Oxurion NV Logo

Oxurion NV

Acquires European pharmaceutical subcontractors to build an integrated healthcare services group.

OXUR | BR

Overview

Corporate Details

ISIN(s):
BE0974487192
LEI:
549300VWY8KVDFKLDM59
Country:
Belgium
Address:
Gaston Geenslaan 1, 3001 Heverlee
Sector:
Mining and quarrying
Industry:
Mining of non-ferrous metal ores

Description

Oxurion is a company specializing in acquiring majority stakes in promising European pharmaceutical subcontractors. Its ambition is to build an integrated group of subcontractors to serve healthcare stakeholders. The company holds a 72% stake in Axiodis CRO, a contract research organization specialized in biometrics. This strategy represents a shift from its historical focus as a biopharmaceutical company developing therapies for retinal diseases like Geographic Atrophy (GA) and Age-related Macular Degeneration (AMD).

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-10-02 18:00
Major Shareholding Notification
OXUR-Transparency-Notification-EN-20251002.pdf
English 352.2 KB
2025-10-02 18:00
Major Shareholding Notification
OXUR-Transparency-Notification-NL-20251002.pdf
Dutch 378.2 KB
2025-09-30 18:00
Interim Report
OXUR GLOBAL - Financial report 30-06-2025 (EN) FINAL.pdf
English 412.9 KB
2025-09-30 18:00
Interim Report
OXUR GLOBAL - Financial report 30-06-2025 (NL) FINAL.pdf
Dutch 420.8 KB
2025-09-30 18:00
Report Publication Announcement
OXUR_Publish-H1-2025-results_EN.pdf
English 211.4 KB
2025-09-30 18:00
Report Publication Announcement
OXUR_Publication-H1-2025-resultats_FR.pdf
French 161.8 KB
2025-09-30 18:00
Report Publication Announcement
OXUR_Publicatie-H1-2025-resultaten_NL.pdf
Dutch 211.0 KB
2025-09-08 18:00
Major Shareholding Notification
OXUR-Transparency-Notification-EN-20250903.pdf
English 371.9 KB
2025-09-08 18:00
Major Shareholding Notification
OXUR-Transparency-Notification-NL-20250903.pdf
Dutch 396.3 KB
2025-09-01 18:00
Capital/Financing Update
OXUR-Contrat-atlas-crypto-EN-20250901.pdf
English 190.2 KB
2025-09-01 18:00
Capital/Financing Update
OXUR-Contrat-atlas-crypto-FR-20250901.pdf
French 125.2 KB
2025-09-01 18:00
Capital/Financing Update
OXUR-Contrat-atlas-crypto-NL-20250901-1.pdf
Dutch 214.2 KB
2025-09-01 18:00
Major Shareholding Notification
OXUR-Transparency-Notification-EN-20250901.pdf
English 1.2 MB
2025-09-01 18:00
Major Shareholding Notification
OXUR-Transparency-Notification-NL-20250901.pdf
English 1.3 MB
2025-08-07 18:00
Legal Proceedings Report
OXUR-New-Development-Strategy-EN-20250806.pdf
English 195.7 KB

Automate Your Workflow. Get a real-time feed of all Oxurion NV filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for Oxurion NV via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2022-03-07 Bareldam SA Close relation Buy 1,180,555 1,700,000.00 EUR
2021-09-30 Lavinia D. Clay 2009 Revocable Trust Close relation Other 2,766,337 5,601,002.52 EUR

Peer Companies

Company Country Ticker View
Developing novel cancer immunotherapies, including peptide vaccines and iPS-NKT cell therapies.
Japan 4594
Brilliant Future AB Logo
A data-driven survey platform to measure and improve employee & customer experiences.
Sweden BRILL
b-style holdings,Inc. Logo
Offers flexible staffing for homemakers and specialized recruitment for skilled professionals.
Japan 302A
BTS Group Logo
Helps organizations execute strategy via experiential learning for leadership and sales teams.
Sweden BTS
B.U Technology Logo
Commercializes university research via IP management, licensing, and new venture creation.
South Korea 230980
Advancing high-grade copper and precious metal projects from discovery to production.
Canada N/A
Cantargia Logo
Develops antibody treatments targeting IL1RAP for cancer and autoimmune/inflammatory diseases.
Sweden CANTA
Captor Therapeutics S.A. Logo
Developing TPD therapeutics for oncology and autoimmune diseases with its Optigrade™ platform.
Poland CTX
Offers one-stop BPO, CRM, and staffing for admin, manufacturing, and logistics.
Japan 6070
Carna Biosciences, Inc. Logo
Develops kinase inhibitor drugs for oncology/autoimmune diseases & offers discovery support services.
Japan 4572

Talk to a Data Expert

Have a question? We'll get back to you promptly.